MLchartDataset catalogue

SLC6A8 inhibitor RGX-202

Term · Oncology and biomedicine · MLC-T-ONC-016771

An orally available, small molecule inhibitor of the creatine transporter, solute carrier family 6, member 8 (SLC6a8), with potential antineoplastic activity. Upon oral administration, RGX-202 inhibits phosphocreatine uptake by SLC6a8, thereby reducing intracellular levels of phosphocreatine available for ATP synthesis in tumor cells. SLC6a8 is overexpressed in some cancer types and inhibition of its activity may potentially limit tumor cell growth and metastasis.

Table 1. Record
IdentifierMLC-T-ONC-016771
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-016771",
  "term": "SLC6A8 inhibitor RGX-202",
  "field": "Oncology and biomedicine",
  "definition": "An orally available, small molecule inhibitor of the creatine transporter, solute carrier family 6, member 8 (SLC6a8), with potential antineoplastic activity. Upon oral administration, RGX-202 inhibits phosphocreatine uptake by SLC6a8, thereby reducing intracellular levels of phosphocreatine available for ATP synthesis in tumor cells. SLC6a8 is overexpressed in some cancer types and inhibition of its activity may potentially limit tumor cell growth and metastasis.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/slc6a8-inhibitor-rgx-202/"
}

Record 15,072 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.